Drug Trial Radar · NCT07307235
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,316
Planned (sponsor's estimate)
Start
Dec 13, 2025
Primary completion
Jun 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi (China) Investment Co., Ltd
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT). It will compare the efficacy and safety of iGlarLixi versus standard of care in adult T2DM patients with poor glycemic control, who are using 1 to 3 OADs in a real-world clinical practice setting. A total of 1,316 subjects from approximately 40 research centers in China will be randomly assigned in a 1:1 ratio to one of the following treatment groups: Group 1: iGlarLixi for blood glucose control; and Group 2: Standard of care for diabetes (basal insulin or premixed insulin, excluding any GLP-1RA-containing drugs). Considering the substantial difference in intervention methods between the two groups, the study is designed as non-blinded with an open-label approach.
Conditions
- Type 2 Diabetes
Interventions
iGlarLixi (insulin glargine/lixisenatide)Drug
The investigational drug is iGlarLixi. Participants will receive subcutaneous injections of iGlarLixi with the OAD treatment regimen being appropriately maintained or adjusted as intensification therapy in routine clinical practice.
standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)Drug
The control drug treatment is standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs). Participants will receive standard of care with the OAD treatment regimen being maintained or appropriately adjusted as an intensification treatment during routine clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- hemoglobin A1c (HbA1c) changeTime frame: from baseline to week 24
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of USTC / Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
The First People's Hospital of Huizhou
Huizhou, Guangdong, China · Recruiting
Shenzhen Third People's Hospital
Shenzhen, Guangdong, China · Recruiting
Heilongjiang Provincial Hospital
Harbin, Heilongjiang, China · Recruiting
Xinxiang Central Hospital
Xinxiang, Henan, China · Recruiting
Wuhan Fourth Hospital / Wuhan Puai Hospital
Wuhan, Hubei, China · Recruiting
Hunan Provincial People's Hospital / The First Affiliated Hospital of Hunan Normal University
Changsha, Hunan, China · Recruiting
Hengyang Central Hospital
Hengyang, Hunan, China · Recruiting
Affiliated Nanhua Hospital, University of South China
Hengyang, Hunan, China · Recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Clinical Hospital of Jilin Academy of Chinese Medicine Sciences
Changchun, Jilin, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Tenth People's Hospital / Tenth People's Hospital of Tongji University
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai East Hospital, Tongji University
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pudong New Area Punan Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Minhang Hospital, Fudan University / Central Hospital of Minhang District, Shanghai
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Qingpu District Central Hospital / Qingpu Branch of Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Recruiting
Jiaxing First Hospital
Jiaxing, Zhejiang, China · Recruiting
Ningbo No. 2 Hospital
Ningbo, Zhejiang, China · Recruiting
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.